Brain Cancer | Topics

New Research Examines the Impact of Ethnicity on Overall Survival in Brain Cancer
November 11, 2021

Patients who are White British and have been diagnosed with a malignant primary brain tumor were found to have a shorter survival compared with patients of other ethnicities.

FDA Grants Rare Pediatric Disease Designation to 177Lu-omburtamab-DTPA for Medulloblastoma
October 11, 2021

Pediatric patients with medulloblastoma may experience benefit from 177Lu-omburtamab-DTPA, which was granted a rare pediatric disease designation by the FDA.

FDA Breakthrough Device Designation Granted to Alpha DaRT in Recurrent Glioblastoma
October 08, 2021

The Alpha DaRT system was granted breakthrough device designation by the FDA for the treatment of glioblastoma.

Carboplatin Therapy Intensification Results in Improved 5-Year EFS in Pediatric High-Risk Group 3 Medulloblastoma
August 11, 2021

Pediatric patients with high-risk molecular subgroup group 3 medulloblastoma experienced an improvement in 5-year event-free survival after receiving therapy intensification with carboplatin.

DAY101 Granted Rare Pediatric Disease Designation by the FDA for Pediatric Low-Grade Glioma
July 28, 2021

The phase 2 clinical trial is currently recruiting patients with pediatric low-grade glioma to be treated with DAY101 following a rare pediatric disease designation by the FDA.

FDA Grants Fast Track Designation to Berubicin For Treatment of Recurrent Glioblastoma Multiforme
July 05, 2021

Based on its potential to prolong overall survival in patients with glioblastoma multiforme, berubicin was granted fast track designation for the FDA for the treatment of recurrent disease.

Medical World News® Inside the Practice: CancerNetwork® and Albert H. Kim, MD, PhD, on Treating Brain Tumor Malignancies at the Siteman Cancer Center
May 28, 2021

CancerNetwork® spoke with Albert H. Kim, MD, PhD, about a new Brain Tumor Center at Siteman, for which he is the inaugural director.

Clinical Benefit Observed With Dabrafenib Plus Trametinib Combo for Glioma Subtypes
April 15, 2021

A durable clinical benefit was seen from the dual inhibition of the MAPK pathway using BRAF and MEK inhibitors dabrafenib and trametinib, respectively, to treat patients with BRAF V600E mutant low- and high-grade glioma.

Pathogenic Germline Variants Correlate With Worse Survival Outcomes in Neuroblastoma
April 11, 2021

Germline variants in cancer predisposition genes were associated with worse event-free and overall survival in patients with neuroblastoma.

FDA Recommends Early Termination of Phase 2 Trial Investigating ERC1671 to Treat Glioblastoma
April 09, 2021

ERC-USA announced that the FDA recommended the early termination of a phase 2 clinical trial of ERC1671 to treat patients with recurrent or progressive glioblastoma and pursue a randomized confirmatory phase 3 trial.